(Q38107175)

29 August 2017

title

Clinical pharmacology of axitinib (English)

1 reference

29 August 2017

1 reference

Ying Chen

1

1 reference

29 August 2017

Michael A Tortorici

2

1 reference

29 August 2017

May Garrett

3

1 reference

29 August 2017

Brian Hee

4

1 reference

29 August 2017

Karen J Klamerus

5

1 reference

29 August 2017

Yazdi K Pithavala

6

1 reference

29 August 2017

publication date

1 September 2013

1 reference

Clinical Pharmacokinetics

29 August 2017

published in

1 reference

29 August 2017

volume

52

1 reference

29 August 2017

issue

9

1 reference

29 August 2017

page(s)

713-725

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-013-0068-3

29 August 2017

exact match

0 references

cites work

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Axitinib for the management of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Development of second-generation VEGFR tyrosine kinase inhibitors: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Pharmacokinetic evaluation of axitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Concise drug review: pazopanib and axitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

The Simcyp population-based ADME simulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-013-0068-3

Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin

21 January 2018

1 reference

12 December 2020

Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine

1 reference

12 December 2020

Physiological parameters in laboratory animals and humans

1 reference

12 December 2020

When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective

1 reference

12 December 2020

Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations

1 reference

12 December 2020

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

1 reference

12 December 2020

A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers

1 reference

12 December 2020

Axitinib for renal cell carcinoma

1 reference

12 December 2020

10.1007/S40262-013-0068-3

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1007267484

0 references

1 reference